N-(2-Chloro-6-Methylphenyl)-2-[[6-[4-[2-(2-Ethoxyethoxy)Ethyl]Piperazin-1-Yl]-2-Methylpyrimidin-4-Yl]Amino]-1,3-Thiazole-5-Carboxamide置于三氯化硼体系中,用 二氯甲烷 作为反应溶剂,以72.5%的收率获得产物达沙替尼 参考文献:Synthesis Process Of Dasatinib And Intermediate Thereof 标题:Synthesis Process Of Dasatinib And Intermediate Thereof 摘要:公开了达沙替尼的合成过程,其中包括将式i的化合物与式ii的化合物反应,以获得式iii的化合物.还公开了式iii的化合物,该化合物用作合成达沙替尼的中间体.式i,Ii或iii中的r1,R2,R3或r4的取代基如描述所定义.
专利号:US-12383499-B2 优先权日:2018-01-01 标题:Scale up synthesis of silicasome nanocarriers 发明人:NEL ANDRE E; MENG HUAN; LIU XIANGSHENG 权利人:UNIV CALIFORNIA 摘要:In order to facilitate the approval and commercialization of silicasome drug delivery systems (e.g. irinotecan silicasomes) it is necessary to scale up synthesis of the drug-loaded silicasomes. In this regard, it was discovered that the synthesis protocols used for laboratory synthesis of drug-loaded silicasomes (e.g., 500 mg/batch) do not scale to large scale silicasome production, because the resulting products were too heterogeneous for use as pharmaceuticals. Accordingly, new methods are provided herein that effectively afford the large-scale production of mesoporous silica nanoparticles (MSNPs) and lipid bilayer coated MSNPs (silicasomes).
专利号:US-10973847-B2 优先权日:2017-06-30 标题 :Core-to-surface polymerization for the synthesis of star polymers and uses thereof 发明人:JOHNSON JEREMIAH A; GOLDER MATTHEW R 权利人:MASSACHUSETTS INST TECHNOLOGY 摘要:Disclosed are methods, compositions, reagents, systems, and kits to prepare star polymers, as well as compositions and uses thereof. Various embodiments show that synthesis of these polymers contain low metal concentration to provide polymers for diverse biomedical applications including in vivo applications.
专利号:US-12240835-B2 优先权日:2018-09-18 标题:Substituted benzamides as intermediates in the synthesis of inhibitors of tyrosine kinase enzymatic activity 发明人:ROMERO F ANTHONY; KIRSCHBERG THORSTEN A; HALCOMB RANDALL; XU YINGZI 权利人:TERNS PHARMACEUTICALS INC 摘要:Provided herein are compounds, preferably compounds inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, compositions thereof, and methods of their preparation, and methods of inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, and methods for treating diseases wherein modulation of BCR-ABL1 activity prevents, inhibits, or ameliorates the pathology and/or symptomology of the disease. Intermediates such as compounds of Formula (S23), which are useful in the synthesis of compounds inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, are also provided.
专利号:WO-2022146324-A1 优先权日:2020-12-29 标 题 :Synthesis of pyrimidine-4(lh)-one derivatives from new hydrazineylidene 发明人:SARIPINAR EMIN; BURCU HILAL JANSET; KEKEÇMUHAMMED HÜSEYIN; TAPERA MICHAEL 权利人:T C ERCIYES UENIVERSITESI 摘要:This invention relates to the synthesis of pyrimidine-4 (1H)-one derivatives from Meldrum's acid, carbonyl compounds (aldehyde/ketone), and guanylhydrazone derivatives and tautomers, enantiomers, and salts thereof.
专利号:US-2024209029-A1 优先权日:2021-04-21 标题:Adiponectin glycopeptides and compositions and methods of use thereof 发明人:WANG YU; LI XUECHEN; XU AIMIN; WU HONGXIANG; ZHANG YIWEI; LI YUANXIN 权利人:UNIV HONG KONG 摘要:An improved method for the chemical synthesis of glycosylated peptides has been developed. The method uses stereoselective glycan synthesis and chemical peptide ligation to produce glycopeptides at lower-cost and with higher efficiency/yield compared to conventional methods. In particular, a method for the large-scale, chemical synthesis of hydroxylated amino acid building blocks and glycosylated amino acids suitable for solid phase peptide synthesis (SPPS) are disclosed. SPPS-based methods using the glycosylated amino acids to chemically synthesize adiponectin-like peptides are also described. In vivo studies show that the adiponectin mimicking glycopeptides exhibit significant anticancer, anti-obesity and insulin sensitizing effects. Pharmaceutical compositions of the synthetic glycopeptides and methods of use thereof in treating diseases associated with deficient adiponectin are also described.
专利号:WO-2017100796-A1 优先权日:2015-12-11 标 题 :Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers 发明人:WONG CHI-HUEY; HSU TSUI-LING; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI 权利人:SINACA ACAD; WONG CHI-HUEY; HSU TSUI-LING 摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta- 4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for disgnostic and therapeutic uses.
1: Lindauer M, Hochhaus A. Dasatinib. Recent Results Cancer Res. 2018;212:29-68. doi: 10.1007/978-3-319-91439-8_2. 120(2-3):52-63. doi: 10.14712/23362936.2019.10. 17(2):78-82. doi: 10.1016/j.clml.2016.09.012. Epub 2016 Sep 17. 16(1):190. doi: 10.1186/s12974-019-1561-x. 5: Levêque D, Becker G, Bilger K, Natarajan-Amé S. Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib. Clin Pharmacokinet. 2020 Jul;59(7):849-856. doi: 10.1007/s40262-020-00872-4. 47:446-456. doi: 10.1016/j.ebiom.2019.08.069. Epub 2019 Sep 18. Erratum in: EBioMedicine. 2020 Feb;52:102595.
合成参考文献
参考文献:10.1016/j.bmc.2010.01.056 摘要:Mashkani B, Griffith R, Ashman LK. Colony stimulating factor-1 receptor as a target for small molecule inhibitors. Bioorg Med Chem. 2010 Mar 01;18(5):1789–97. doi: 10.1016/j.bmc.2010.01.056. 参考文献:10.1007/s12094-010-0476-x 摘要:García de Polavieja Carrasco M, de Juan Ferré A, Mayorga Fernández M. Gastrointestinal stromal tumours at present: an approach to burning questions. Clinical and Translational Oncology. 2010 Feb 20;12(2):100–12. doi: 10.1007/s12094-010-0476-x. 摘要:Burney IA, Al-Moundhri MS. Major Advances in the Treatment of Cancer: What does a Non-Oncologist need to know Sultan Qaboos Univ Med J. 2008 Jul;8(2):137–48. 参考文献:10.1002/pros.21435 摘要:George D, Moul JW. Emerging treatment options for patients with castration-resistant prostate cancer. Prostate. 2012 Feb;72(3):338–49. doi: 10.1002/pros.21435. 参考文献:10.1021/pr200344n 摘要:Caccia D, Zanetti Domingues L, Miccichè F, De Bortoli M, Carniti C, Mondellini P, Bongarzone I. Secretome compartment is a valuable source of biomarkers for cancer-relevant pathways. J Proteome Res. 2011 Sep 02;10(9):4196–207. doi: 10.1021/pr200344n.